The difference between information and
expert, data-driven actionable intelligence


March 2017

Welcome to the March 2017 issue of CMC Market Outlook

This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.

Enjoy the March issue!

The PharmSource Team


AGC Acquires CMC Biologics

UAGC Asahi Glass has agreed to acquire biomanufacturer CMC Biologics in a deal valued at ¥60 billion ($500 million). PharmSource estimates that the price represents a multiple of about 3.3x revenues and more than 10x EBITDA. The selling shareholders are three private equity firms: Monitor Clipper Partners; European Equity Partners; and Innoven Partenaires.

This is AGC’s second acquisition of a biomanufacturing business in the past six months. In September 2016, it acquired… read on

Will Pharma Manufacturing Move Back to the US?

by Jim Miller, President

The bio/pharmaceutical industry is still buzzing about President Trump’s meeting with pharmaceutical executives on Jan. 31, 2017. While promising the industry lower taxes and less regulation, the President emphasized that those benefits will come only if the industry lowers drug prices and moves more manufacturing back to the United States.

The President’s insistence that manufacturing move back to the US set off a wave of promises from the bio/pharmaceutical industry about the number of jobs that might be created, including a projection by… read on

Where’s your place in the CMO hierarchy?

Find out in the CMO industry’s authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its performance over time, and CMOs to benchmark their performance against the industry.

Our research team crunched the numbers on 2016 drug approvals authorized by FDA’s CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. For the first time, we are including information on the location of outsourced dose manufacturing facilities. CMO Scorecard concludes that 2016 was not a halcyon year for new drug approvals with only 25 NMEs approved since 2010.


DCAT Week 2017

Pharma Outsourcing: The Numbers, Trends and Partnership Strategies
PharmSource president Jim Miller will provide an in-depth analysis of the market for contract development and manufacturing for drug substances and drug products, including levels of outsourcing, capacity utilization, trends in capital expenditures impacting outsourcing, and strategies for supplier differentiation today at 9:15 am in the Grand Ballroom at the InterContinental Barclay.

Bio/Pharmaceutical Outsourcing Report – Special DCAT Edition
Check out the special DCAT Edition of PharmSource’s proprietary industry briefing.

This monthly report reports on and analyzes major developments throughout the CMO industry. It provides expert insight into the significance of industry trends and what they mean for your business.

Deepen your understanding of what’s happening in commercial and clinical dose manufacturing and packaging, API small and large molecule, captive capacity, regulatory developments and more. Get your copy from the PharmSource team at DCAT. Or click here to download your complimentary copy.


PharmSource Strategic Advantage

Let PharmSource be your market intelligence guide.

PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.

See for yourself how this resource gives you vital tools for understanding the industry.

To request a test-drive today, contact / +1-703-383-4903, ext. 112.